Association Between Voiding Dysfunction and Intravesical Recurrence in Non-Muscle-Invasive Bladder Cancer
This retrospective study demonstrates that higher preoperative post-void residual (PVR) volume and PVR ratio are independent predictors of intravesical recurrence in male patients with non-muscle-invasive bladder cancer, whereas conventional uroflowmetric parameters show limited discriminatory ability.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Bladder cancer is a common disease where abnormal cells grow on the inner lining of the bladder. In most cases, these tumors do not grow deep into the muscle wall, a condition doctors call non-muscle-invasive bladder cancer. The standard treatment involves a procedure to scrape the tumor out through a tube passed up the urethra, followed by regular check-ups to ensure the cancer does not return. While doctors have long used factors like the size of the tumor and how aggressive the cells look under a microscope to predict who might get sick again, these tools are not perfect. Many patients still face a recurrence, and researchers are constantly looking for other clues hidden in a patient's daily life or body function that could help predict the future. One such area of interest is how well the bladder empties itself. When a person urinates, some urine often remains inside; this leftover amount is called post-void residual urine. If too much urine stays behind, it sits in the bladder for longer periods, potentially exposing the delicate inner lining to harmful substances in the urine for an extended time.
A team of researchers at Hitit University in Turkey set out to investigate whether this leftover urine volume could be a warning sign for bladder cancer returning. They focused specifically on men who had undergone surgery to remove non-muscle-invasive bladder tumors. The team reviewed the medical records of hundreds of patients who had been treated between 2018 and 2026, but they could only include those who had complete records of their bladder function tests before the surgery. After filtering out patients who did not have these specific measurements or who did not provide enough urine for a reliable test, the final group consisted of 106 men. The researchers divided these men into two groups: those whose cancer came back during their follow-up period and those whose cancer did not return. They then compared the two groups to see if there were any differences in how their bladders emptied, looking at both the amount of urine left behind and the speed of the urine flow.
The results revealed a striking difference between the two groups. Among the men whose cancer returned, the amount of urine left in the bladder after they finished urinating was significantly higher than in the men who remained cancer-free. On average, the men with a recurrence had 250 milliliters of urine left in their bladders, whereas the men without a recurrence had only 50 milliliters. This difference was so clear that the researchers could use the amount of leftover urine to predict recurrence with very high accuracy. In contrast, other measurements of bladder function, such as how fast the urine flowed or the total volume of urine passed, showed no significant difference between the two groups. This suggests that it is not the speed of urination that matters, but rather the failure to empty the bladder completely.
To understand the strength of this connection, the researchers calculated the odds of recurrence based on the amount of leftover urine. They found that for every increase of 50 milliliters in the leftover urine volume, the likelihood of the cancer returning rose dramatically. Even when they adjusted their calculations to account for other known risk factors, such as the patient's age, the stage of the tumor, and whether the patient received additional drug treatments inside the bladder, the amount of leftover urine remained a powerful independent predictor. The study also identified a specific threshold: men who had 150 milliliters or more of urine left in their bladder after urinating were at a much higher risk of recurrence. In fact, no men with less than 150 milliliters of leftover urine experienced a recurrence in this study group. This finding suggests that a simple, non-invasive test to measure leftover urine could help doctors identify patients who need closer monitoring.
However, the researchers were careful to note that this study has limitations. Because it looked back at past records from a single hospital, the findings need to be confirmed by larger, forward-looking studies involving many different centers. The specific cutoff of 150 milliliters was derived from this particular group of patients and has not yet been tested on a different population, so it should be viewed as a promising clue rather than a final rule for clinical practice. Furthermore, the study only included men, so it is not yet known if these same patterns apply to women. Despite these caveats, the study provides a compelling new perspective. It suggests that the mechanics of how a patient empties their bladder may hold a key piece of information that current risk models miss. By measuring the simple volume of urine left behind, doctors might soon have a clearer picture of which patients are most vulnerable to the return of their disease, allowing for more personalized and effective care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.